Objective: Aim of the study was to assess the efficacy and safety of levetiracetam as add-on treatment in patients with partial-onset epilepsy in clinical practice. Methods: In this observational, multi-centre study patients were treated with levetiracetam for 16 weeks. From a starting dose of 1000 mg/day, dose levels were adjusted at 2-weekly intervals in 1000-mg steps, to a maximum of 3000 mg/day, based on seizure control and tolerance. Analysis of efficacy was based on reduction in seizure frequency relative to baseline, 50% and 100% responder rates (for partial seizures and all seizure types combined) and percentage of patients using levetiracetam at the end of the study. Analysis of safety was based on occurrence of adverse events.
Introduction
Epilepsy is a very common neurological disorder affecting around 50 million people world-wide. 1 Partial epilepsies, related to a focal brain dysfunction, are the most frequently occurring types, accounting for approximately 60% of cases.
2 Though treatment with anti-epileptic drugs, either as monotherapy or as a combination of two or more compounds, is effective in the majority of patients, seizure control has been reported to be inadequate in about 25% of the patients. 3 Levetiracetam (Keppra 1 , UCB Pharma, Belgium) is a new anti-epileptic compound, which has been registered in the USA, the EU and several other countries world-wide as add-on therapy in the treatment of adult epileptic patients with partial-onset seizures with or without secondary generalization. Levetiracetam is chemically unrelated to other antiepileptic drugs and its exact mechanism of action also appears to be different. 4 The properties considered likely to be related to the anti-epileptic activity are: specific binding to the synaptic vesicle protein 2A (SV2A) in the brain, 5 selective inhibition of high voltage-activated (N-type) calcium channels, 6, 7 reduction of Ca 2+ release from intraneuronal stores (ryanodine receptors) 8 and reversal of the inhibition by negative allosteric modulators of GABA-and glycine-gated currents (zinc, b-carbolines) . 9 Levetiracetam has a very favourable pharmacokinetic profile 10 with rapid and complete absorption, very low protein binding and elimination mainly by renal excretion with limited metabolization, which results in linear pharmacokinetics and absence of interactions with concomitantly used drugs, including other anti-epileptic drugs. [10] [11] [12] The efficacy of levetiracetam as add-on treatment in partial-onset epilepsies has been shown in a number of clinical studies. In placebo-controlled trials in refractory patients [13] [14] [15] [16] (review published by Privitera 17 ), levetiracetam was shown to significantly reduce seizure frequency, with a substantial percentage of patients becoming seizure free, and with high responder rates in the remaining patients.
All dose levels in the 1000-3000 mg per day dose range were superior to placebo, with the extent of efficacy being dose-related. 18 Levetiracetam has been shown to have a rapid onset of action, 19 to be effective in all partial seizure subtypes (simple and complex partial seizures and secondary generalized seizures), 20 and to retain its effectivity during long-term use. 21 Treatment with levetiracetam was very well tolerated, without major differences in adverse events between levetiracetam and placebo, [13] [14] [15] [16] except for a higher incidence of somnolence, asthenia, dizziness and headache. There was no clear dose-response relationship for adverse events. Adverse events were generally mild to moderate in severity.
Results from two large Phase IV observational studies, the KEEPER TM (Keppra 
Materials and methods

Design
The study was designed as a Phase IV, prospective open-label, multicentre study on the efficacy and safety of levetiracetam as add-on therapy in the treatment of partial-onset seizures in epileptic patients in clinical practice. Patients were to be treated for 16 weeks at dose levels between 1000 and 3000 mg/day, to be determined during individual titration based on seizure control and tolerance. A total of 1548 patients were included by 248 study centres world-wide. The current publication describes the full results obtained in patients recruited in Belgium (42 centres) and The Netherlands (14 centres 24 Patients were to have at least one and not more than fourteen partial seizures per month, calculated as mean seizure frequency over the 3-month period preceding the selection visit. They were to use one or two concomitant marketed anti-epileptic drugs at baseline, to be used for at least 4 weeks before the first visit at a stable dose regimen. Benzodiazepines used on a daily basis were considered as one of the concomitant anti-epileptic drugs, regardless of the prescribed indication.
Patients were not included if they had experienced pseudoseizures within the last year, or uncountable seizures (clusters) or a history of convulsive status epilepticus within the last 5 years. The following medical conditions were also reasons for exclusion: a history of suicide attempt or current suicidal ideation or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous 5 years, presence of progressive cerebral disease, any other progressively degenerative neurological disease or any cerebral tumours or presence of a terminal illness or any medical condition that might interfere with the patient's study participation (including scheduled elective surgery), as well as haematological abnormalities (absolute neutrophil counts <1800/ mm 3 and/or platelet count <100,000/mm 3 ), or any disorder or condition affecting pharmacokinetic behaviour of drugs (such as severe renal or hepatic impairment; patients with mild or moderate renal impairment could be included with appropriate dose adjustment).
Previous exposure to levetiracetam, presence or history of allergy to levetiracetam (or related substances) or to one of components of levetiracetam tablets, participation in a clinical trial within 12 weeks of the selection visit, use of felbamate with less than 18 months of exposure, or use of vigabatrin without the recommended assessment of visual field were also reasons for exclusion. Pregnant or lactating women were not to be included, and women of childbearing potential were to use a reliable and medically acceptable form of birth control.
Treatment
Patients received levetiracetam tablets (Keppra 1 500 mg tablets; UCB Pharma, Belgium), to be taken twice daily. All patients started at 1000 mg/day. If seizure control was considered to be insufficient after 2 weeks of treatment, the dose level was increased to 2000 mg/per day, provided the medication was well tolerated. If after 4 weeks of treatment seizure control was still insufficient, but tolerance acceptable, the dose level was increased to 3000 mg/day. Between Week 4 and the end of the study the dosage could be modified at any time (increased or decreased in 1000-mg steps within the 1000-3000 mg/day dose range), to a level of optimal balance between seizure control and tolerance.
In case of mild (creatinine clearance 50-79 ml/ min) or moderate (creatinine clearance 30-49 ml/ min) renal insufficiency the daily dose was to be adjusted to a dose of 1000-2000 mg/day and 500-1500 mg/day, respectively.
When treatment with levetiracetam was to be withdrawn the daily dose should be decreased gradually by 1000 mg every 2 weeks.
To allow proper evaluation of the effects of levetiracetam concomitant anti-epileptic treatment was to remain unchanged during the study, and was only allowed to be changed when considered medically necessary.
Assessments
At the selection visit patients gave informed consent and their compliance with the entrance criteria was confirmed. Medical history was obtained, including history of epilepsy (with aetiology) and history and current use of antiepileptic medication. Historical seizure count (number of seizures per seizure type for the past 3 months) was determined. Patients were examined physically and neurologically, and a blood sample was taken for haematological and biochemical screening.
Study visits were planned after 2, 4, 10 and 16 weeks of treatment.
The number and type of seizures were recorded by the patients on daily record cards, which were evaluated at each treatment visit. Seizures were coded by the investigator using the International Classification of Epileptic Seizures. 24 Any changes in levetiracetam dose and in concomitant antiepileptic medication were documented. Exposure to the study medication was determined by counting unused medication and ensuring that non-returned medication had indeed been used. Information on occurrence of adverse events and serious adverse events was obtained through observation by the investigator, spontaneous reporting by the patient and active questioning of the patients by the investigator.
After the 16-week study period patients could choose to continue with levetiracetam treatment on a prescription basis. Adverse events monitoring was then to be continued. If patients discontinued treatment at the end of the study (following the withdrawal dosing scheme described above) they were to return for a safety visit 2 weeks following the last levetiracetam dose. At this safety visit evaluation of seizures, physical and neurological examination, documentation of changes in antiepileptic and other concomitant medication and assessment of adverse events was performed.
Statistical analysis
Both the efficacy and safety analysis were performed on the Intention-to-Treat (ITT) population, which was defined as the population of patients included in the study, who took at least one dose of study medication.
Efficacy was assessed as the percentage reduction from baseline in seizure frequency, the 50% responder rate (i.e., percentage of patients with a reduction in seizure frequency of more than 50%) and the 100% responder rate (percentage of patients becoming free of seizures). All efficacy parameters were calculated separately for Type I seizures (partial-onset or focal seizures) and for all seizures types combined (Type I = partial-onset or focal seizures; Type II = generalized seizures, convulsive or nonconvulsive; and Type III = unclassified epileptic seizures).
The retention rate, defined as the number of patients taking levetiracetam at the end of the 16-week treatment period divided by the total number of patients included in the study, was also used as a measure of efficacy.
Safety analysis focused on the nature, incidence and severity of adverse events.
Results
Study population and extent of exposure
A total of 251 patients were included in the study and constituted the ITT population (Table 1) . 86.9% of the patients completed all 16-weeks of study duration. Demographic data and characteristics of epilepsy of the study population are presented in Table 2 Table 2 ). Type 1B (complex partial seizures with impairment of consciousness) was the most frequently reported seizure type (78% of the patients), with Type IA seizures (simple partial seizures without impairment of consciousness) and Type IC (partial seizures evolving to secondarily generalized seizures) being reported in 34% and 37% of patients, respectively. Generalized seizures (Type II) occurred in only 7% of the patients ( Table 2) .
Aetiology of epilepsy was reported to be ''unknown'' for most patients (39%), followed by cranial trauma (9.2%) and congenital malformation (8.4%). Most patients (87.3% of the study population) had previously used one or more antiepileptic drugs, the number of different antiepileptic drugs in history being (% of the patients in brackets) 1 (21.1%), 2 (15.1%), 3 (15.9%), 4 (10.8%), 5 (13.5%), 6 (4.0%), 7 (3.2%), 8 (2.4%) or 9 (0.8% of the patients).
In accordance with the protocol most patients used 1 (39.4%) or 2 (57.0%) antiepileptic drugs at study entry, with carbamazepine, lamotrigine and valproic acid being the most frequently used compounds (Table 3 ). Mean duration of exposure was 109.8 days (S.D. = 30.2), with a mean daily dose of 1690.5 mg (S.D. = 277.9) ( Table 1 ). There were no marked differences in exposure between men and women or between the different age categories.
Efficacy
Levetiracetam, when used as add-on treatment in patients on stable anti-epileptic medication, reduced seizure frequency (number of seizures per week) of partial seizures (Type I) by 62.2% and of all seizure types combined (Types I + II + III) by 61.7% (Table 4) . A substantial percentage of patients became completely seizure-free (19.3% for partial seizures and 18.5% for all seizure types combined) (Fig. 1a and b) . The 50%-responder rate was 56.6% for both partial seizures and all seizure types combined. The percentages calculated for partial seizures only and for all seizure types combined do not differ substantially, because of the low number of patients with Type II and Type III seizures at baseline (7% and 4% of the population, respectively; Table 2 ).
The efficacy of levetiracetam was reflected in a retention rate of 86.9%, with only 4.4% of the subjects indicating discontinuation because of lack of efficacy (Table 1) . 
Safety
Though 65.3% of the study population experienced at least one adverse event, with 55.4% of the adverse events considered to be related to treatment, in only 10.0% of the patients the adverse events led to premature discontinuation from the study and in another 10.4% to dose change or temporary drug discontinuation (Table 5) . Asthenia, convulsion, and somnolence were the most frequently reported adverse events responsible for premature discontinuation from the study. All adverse events were in general of mild or moderate severity, with only 8.0% of the patients reporting adverse events of severe intensity (some patients reported more than one adverse event of severe intensity). The most frequently reported adverse events (>5% of the patients) were related to the nervous system (somnolence, dizziness, depression), or were general in nature (asthenia, headache) ( Table 6 ). Only one patient reported a serious adverse event (convulsion) that was considered to be related to levetiracetam treatment and led to discontinuation from the study.
Discussion
Patients in clinical practice are more diverse than patients included in randomized controlled clinical trials. Controlled clinical trials usually have strict entrance criteria with respect to age, body weight/ height (BMI), severity of epilepsy, usage of concomitant anti-epileptic medication and comorbidity. The study population in the observational SKATE TM Efficacy and safety of levetiracetam in clinical practice 439 Analysis of the results of the current study population showed that levetiracetam was effective in the treatment of epilepsy when added to a stable regimen of one or two other anti-epileptic drugs. Frequency of partial seizures and of all seizure types combined was reduced by more than 60%. Seizure freedom, which is the ultimate goal of treatment, was obtained in 18-19% of the study population. More than half of the patients were 50% responders (i.e., reported a reduction in seizure frequency of more than 50%).
These results from the subpopulation in Belgium and The Netherlands do not differ substantially from the interim results of 731 patients recruited in all participating countries reported by Steinhoff et al. 23 where 17.2% of the patients became seizure-free, and 49% of patients showed a more than 50% reduction in seizures.
The same level of efficacy was reported in the US KEEPER TM trial which had a somewhat different design and included over 1000 patients in a clinical setting. 22 Freedom of seizures was reported in 20% of the patients included in this study, whereas 57.9% achieved a reduction in partial seizures of more than 50%.
The efficacy in the observational studies appears to be higher than that in the placebo-controlled phase III studies. In the analysis of the pooled data of the three pivotal placebo-controlled trials efficacy was shown to be dose-related, with seizure freedom in 8.6% and a more than 50% reduction in seizures in 41% of the patients receiving 3000 mg/day. 18 This observed difference in level of efficacy may be related to differences in patient population and study design. Though there were no major differences in demographic and baseline epilepsy characteristics (age of onset, duration of epilepsy), median baseline seizure frequency was higher in the Phase III trial population (about 9 per month in the Phase III studies versus 3-4 per month in the observational studies). It can also not be excluded that the population included in the Phase III trials was more refractory to anti-epileptic treatment. Perhaps the milder disease type in the clinical practice resulted in a larger reduction in seizure frequency.
The difference between the open design of the observational studies and the double-blind character of the Phase III trials is also likely to contribute to the observed higher efficacy, since an open design will correct less for a possible placebo effect. Though the way the dose level is selected differs between the studies (randomization to a fixed dose level in the Phase III studies versus individual selection of the dose level for each patient in the observational studies) this can not explain the observed difference in level of efficacy. Efficacy in the SKA-TE TM and KEEPER TM trials is calculated and reported as the average efficacy over the entire 1000-3000 mg dose range, and would therefore be expected to be lower, and not higher, than the efficacy in the 3000 mg dose group in the Phase III trials, given the established dose-response relationship for efficacy. 18 Treatment with levetiracetam was generally well tolerated in the study population presented here, but the percentage of patients reporting adverse events was slightly higher than that reported in placebo-controlled studies (65.3% versus 46.4% 25 ). The percentage discontinuing from the study or having a dose reduction because of adverse events was also slightly higher (20.4% in 15% in the placebo-controlled trials 26 ). These differences may be due to differences in the study population (e.g., higher comorbidity), but since no data on this subject are available, this cannot be substantiated.
The adverse event profile was similar to that observed in the placebo-controlled trials and the KEEPER TM trial, 22 with asthenia, somnolence, dizziness and headache being the most frequently reported adverse events. 26 Adverse events were mainly mild to moderate in severity. The incidence of behavioural adverse events (such as hostility, emotional lability, agitation, anxiety and nervousness) and adverse events related to cognitive disturbances (amnesia, confusion and abnormal thinking) was low, which is in line with previous clinical studies. 27, 28 In conclusion, the results of the SKATE TM study obtained in the study centres in Belgium and The Netherlands show that levetiracetam is effective and safe as add-on treatment for partial-onset seizures in a clinical setting. In line with other observational studies on the effects of levetiracetam, the therapeutic effect in daily clinical practice appears to be even more pronounced than in controlled Phase III trials.
